Ulcerative Tuberculosis in a Patient Treated with Adalimumab
DOI:
https://doi.org/10.2340/actadv.v102.1616Keywords:
TNF alfa inhibitor, tuberculosisAbstract
Abstract is missing (Short Communication)
Downloads
References
Flynn JL, Chan J. Immunology of tuberculosis. Ann Rev Immunol 2001; 19: 93-129.
https://doi.org/10.1146/annurev.immunol.19.1.93 DOI: https://doi.org/10.1146/annurev.immunol.19.1.93
van Zyl L, du Plessis J, Viljoen J. Cutaneous tuberculosis overview and current treatment regimens. Tuberculosis 2015; 95: 629-638.
https://doi.org/10.1016/j.tube.2014.12.006 DOI: https://doi.org/10.1016/j.tube.2014.12.006
Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol 2007; 25: 173-180.
https://doi.org/10.1016/j.clindermatol.2006.05.005 DOI: https://doi.org/10.1016/j.clindermatol.2006.05.005
Barbagallo J, Tager P, Ingleton R, Hirsch RJ, Weinberg JM. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002; 3: 319-328.
https://doi.org/10.2165/00128071-200203050-00004 DOI: https://doi.org/10.2165/00128071-200203050-00004
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015; 372: 2127-2135.
https://doi.org/10.1056/NEJMra1405427 DOI: https://doi.org/10.1056/NEJMra1405427
World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf.
Gómez-Reino JJ, Carmona L, Rodríguez Valverde V, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
https://doi.org/10.1002/art.11137 DOI: https://doi.org/10.1002/art.11137
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992.
https://doi.org/10.1002/art.21137 DOI: https://doi.org/10.1002/art.21137
Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 2018; 8: e022445.
https://doi.org/10.1136/bmjopen-2018-022445 DOI: https://doi.org/10.1136/bmjopen-2018-022445
Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009; 28: 749-756.
https://doi.org/10.1007/s10067-009-1135-x DOI: https://doi.org/10.1007/s10067-009-1135-x
Wong SH, Gao Q, Tsoi KKF, Wu WKK, Tam LS, Lee N, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 2016; 71: 64-72.
https://doi.org/10.1136/thoraxjnl-2015-207811 DOI: https://doi.org/10.1136/thoraxjnl-2015-207811
Pai M, Denkinger CM, Kik S v., Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014; 27: 3-20.
https://doi.org/10.1128/CMR.00034-13 DOI: https://doi.org/10.1128/CMR.00034-13
Doan TN, Eisen DP, Rose MT, Slack A, Stearnes G, McBryde ES. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: a latent-class analysis. PLoS ONE 2017; 12: e0188631.
https://doi.org/10.1371/journal.pone.0188631 DOI: https://doi.org/10.1371/journal.pone.0188631
Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
https://doi.org/10.1183/09031936.00115110 DOI: https://doi.org/10.1183/09031936.00115110
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Outi Varpuluoma, Suvi-Päivikki Sinikumpu, Päivi Jackson, Kaisa Tasanen, Laura Huilaja
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
